ArticleOncotarget2016

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.

Emmanouil Papadakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.